Zacks Investment Research
02 Feb 2026, 15:55 UTC · 33w ago
Verdict
Headline leans bullish. We score KALV +0.80 across two claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
2 claims · scored −1 bearish … +1 bullish
Wall Street analysts have a mean price target for KalVista Pharmaceuticals (KALV) of $33.78, representing a potential 116.4% upside from its current price of $15.61.
So whatA significant gap between current price and consensus analyst targets typically attracts bullish momentum and investor interest.
More positive than 76% of claims this week
There is strong analyst agreement regarding positive earnings estimate revisions for KalVista Pharmaceuticals.
Continue reading
5 related stories
More positive than 84% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 62% of claims this week
Which stocks this story touches
More positive than 84% of ticker scores this week
The article highlights significant potential upside based on analyst price targets and positive earnings estimate revisions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
1h ago
+73.0%
Price agrees with the score
$27.00 vs $15.61 close before publication (Jan 30) · not market-adjusted
KALV chart →